In this study, we further demonstrated that combination therapy with the ATR inhibitor, Berzosertib, which is an intravenously administered small molecule with promising anti-tumor activity in multiple phase I/II clinical trials, significantly promoted the sensitivity of ovarian cancer cells to CDDP resistance. The gene discussed is ATR; the disease is ovarian cancer.